Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.65M rose 8.3% year over year, ahead of the -79.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at -18.3% a year.

Context

  • Stock-based compensation amounted to 856.8% of revenue in FY2025, down 28402.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +8.3% holds above the trailing-twelve-month pace of -79.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.65M-3.3% QoQ
Last fiscal yearDec 2025
$11.14M-81.0% YoY
LTMMar 2026
$11.34M-79.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.3%——
1 year-81.0%——
3-year CAGR-18.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.14M USD
Year-over-year change
-81.0%
4-year CAGR
-7.2%

Stock-Based Compensation vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -79.7% is the lowest of 7, against a peer median of +0.5%.
  • Stock-based compensation amounts to 872.4% of revenue for INBX, versus a peer median of 179.5%.
INBX Competitors
Stock-Based Compensation for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JANXJanux Therapeutics, Inc.LTM Mar 2026$38.79M USD+1.8%+32.7%179.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$36.81M USD-0.7%—32869.6%
GENBGenerate Biomedicines, Inc.FY2025$20.58M USD+5.7%—64.5%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$15.81M USD+199.7%+2009.0%—
ABSIAbsci CorporationLTM Mar 2026$13.53M USD-11.4%+13.5%737.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$11.34M USD-79.7%-18.3%872.4%
IMTXImmatics N.V.LTM Mar 2026€7.38M EUR-44.8%—19.8%
Peer median (excluding INBX) —+0.5%+32.7%179.5%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(81.77M)(145.23M)(239.73M)1.69B(140.06M)
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
Deferred Income Tax(9K)0000
Stock-Based Compensation15.05M20.45M24.85M58.52M11.14M
Change in Working Capital(17.52M)3.16M15.35M52.05M(7.61M)
Accounts Receivables(167K)130K(521K)381K243K
Inventory(11.03M)0000
Accounts Payables(4.64M)(705K)2.11M17.9M(3.3M)
Other Working Capital(1.67M)3.74M13.76M33.77M(4.56M)
Other Non-Cash Items2.73M5.09M5.03M(1.99B)4.25M
Operating Cash Flow(80.32M)(115.3M)(193.31M)(194.41M)(129.79M)
Capital Expenditures(864K)(686K)(4.59M)(2.6M)(31K)
Acquisitions (Net)55K0003K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(809K)(686K)(4.59M)(2.6M)(28K)
Debt Repayment000099.84M
Common Stock Issued40.2M129.74M201.96M71.68M1.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities83.77M128.81M000
Financing Cash Flow83.77M258.55M201.96M71.68M101.45M
Effect of Forex Changes00000
Net Change in Cash2.64M142.56M4.06M(125.33M)(28.38M)
Free Cash Flow(81.19M)(115.99M)(197.9M)(197.01M)(129.83M)

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.